Non-muscle-invasive bladder cancer (NMIBC) rarely pro-gresses after resection, but 30% to 60% of these patients develop a recurrent non-muscle-invasive tumour within three years after resection. The follow-up of bladder cancer patients aiming at the early detection of recurrence is currently conducted by cystoscopy, which patients often experience as painful. Urine-based tumour markers could be a non-invasive alternative, but their performance has not yet been proven. The prospective randomized UroFollow trial examines the performance of markers in comparison with cystoscopy for the detection of recurrent tumours in patients with NMIBC.
Conducting a multicentre controlled phase III-clinical trial to compare the detection of recurrence in patients with NMIBC using FDA-approved (food and drug administration, commercially available, urine-based tumour tests (UroVysion, ImmunoCyt/uCyt+, NMP22) in the "marker arm" vs. cystoscopy in the "usual-care arm".
-cross sectoral-Type of hazard:
rehabilitation, occupational disease, diseases of the respiratory tract (except cancer)Description, key words:
bladder cancer, tumour markers, biomarkers, follow-up